Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3A | P46098 | 3/20 | 0.65 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.55 |
| ▸ | HTR2A | P28223 | 1/20 | 0.55 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.55 |
| ▸ | HRH1 | P35367 | 1/20 | 0.55 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7409421 | 0.98 | HTR3A (0.65) | HTR3AKCNH2HTR2ASLC6A4HRH1 | |
| SCHEMBL7416644 | 0.97 | HTR3A (0.64) | HTR3AKCNH2HTR2ASLC6A4HRH1 | |
| SCHEMBL7413930 | 0.97 | HTR3A (0.64) | HTR3AKCNH2HTR2ASLC6A4HRH1 | |
| SCHEMBL7419706 | 0.97 | HTR3A (0.64) | HTR3AKCNH2HTR2ASLC6A4HRH1 | |
| SCHEMBL7413463 | 0.97 | HTR3A (0.64) | HTR3AKCNH2HTR2ASLC6A4HRH1 | |
| SCHEMBL8939939 | 0.87 | HTR3A (0.66) | HTR3AKCNH2HTR2ASLC6A4HRH1 | |
| SCHEMBL7422412 | 0.86 | HTR3A (0.51) | HTR3AKCNH2HTR2ASLC6A4HRH1 | |
| SCHEMBL7415240 | 0.85 | HTR3A (0.48) | HTR3A | |
| SCHEMBL8940048 | 0.83 | HTR3A (0.70) | HTR3AKCNH2HTR2ASLC6A4HRH1 | |
| SCHEMBL7416784 | 0.81 | HTR3A (0.55) | HTR3AKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-1991016888-A1 | SPIRO[BENZOFURANCYCLOALKANE]CARBOXAMIDES AS 5HT3 ANTAGONISTS | RHONE-POULENC RORER INTERNATIONAL (HOLDINGS), INC. (US) | 1991-11-14 | — | — | WO | disclosed |